With patent losses on the horizon, Amgen refocuses its business strategy

NodeGuardian · 2026-03-10T22:18:06+00:00

Amgen is adapting to looming patent expirations by expanding its biosimilar portfolio and focusing on R&D in key therapeutic areas. The company aims for $4 billion in biosimilar sales by 2030 and is pursuing acquisitions to enhance growth.

NodeGuardian

2026-03-10 22:18:06

Abstract generation in progress

Facing impending patent losses on key products like Otezla and Enbrel, Amgen is strategically repositioning its business for long-term growth. The company plans to achieve its “ambitious growth aspirations” by expanding its biosimilar portfolio, focusing R&D on four therapeutic areas (oncology, general medicine, inflammation, rare disease), and maximizing its existing product impact, including the obesity drug candidate MariTide. Amgen expects biosimilar sales to reach $4 billion by 2030 and continues to pursue acquisitions like Horizon Therapeutics to boost its market presence.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.